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Human high density lipoproteins stimulate endothelin.l release by
cultured human renal proximal tubular cells. The vasoconstrictive and
mitogenic actions of endothelins have been implicated in the pathogenesis
of progressive renal disease. In the present study, we have assessed
whether plasma high density lipoproteins (HDL), the major filtered
urinary lipoprotein in nephrotic states, can influence endothelin-1 (ET-1)
production by cultured human renal proximal tubular cells. Human HDL
was found to stimulate ET-i secretion up to fourfold in a dose- and
time-dependent manner; the effect was greater in subconfluent cultures
than in confluent ones. There was little difference between the stimulator)'
effect of HDL2 and the major HDL subclass, HDL3. Preincubation of the
cells with albumin did not abolish the HDL effect, while partially- or
fully-delipidated HDL3 largely reproduced the effect of whole HDL3.
These findings suggest that stimulation of FT-i secretion was not simply
due to protein or lipid repletion of the cells. Rather, the effect was
mediated by HDL apolipoproteins, although binding to the HDL recep-
tors involved in cellular cholesterol homeostasis was not required as
tetranitromethane-modified HDL3 was an equally effective agonist of
FT-i release. Apolipoprotein (apo) A-I was indirectly implicated in the
process since modified HDL3 in which apoA-II largely replaced apoA-I
was less potent than HDL3. A one hour exposure of the cells to HDL3 was
sufficient to activate ET-i production for the following 12 hours, although
maximum activation required six hours. The activation process appeared
to be independent of both cyclic AMP and protein kinase C (P1(C): HDL3
and phorbol myristate acetate had an additive effect; PKC-depleted cells
remained responsive to HDL3; and the PKC inhibitor, staurosporine, did
not reduce HDL3 stimulation of ET-i production. We conclude that the
apolipoprotein constituents of HDL3 enhance FT-i secretion by cultured
renal tubular cells via a novel PKC-independent pathway. Whether this
action of human HDL on tubular FT-i production also occurs in vivo
merits investigation, since it may have pathophysiological significance for
the progressive tubulointerstitial fibrosis associated with chronic protein-
uria.
There is increasing evidence, both in vitro and in vivo, that
proximal tubular cells secrete an array of cytokines and growth
factors constitutively [1]. These include the endothelins, a recently
discovered family of peptides with potent vasoconstrictor [2],
mitogenic [3] and chemotactic properties [4]. Recently, we de-
scribed endothelin-1 (ET-1) synthesis by human renal proximal
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tubular cells [5] and other workers have shown that animal tubular
cells from a variety of nephron segments synthesize endothelins
[6]. The renal microcirculation appears to be particularly sensitive
to the vasoactive actions of the endothelins [7], while ET-1 is
mitogenic to cultured human renal cortical fibroblasts [8] and
other fibroblast lines [3]. In the rat 5/6 nephrectomy model, a
model of progressive chronic renal failure associated with pro-
teinuria, ET-1 gene expression in the remnant kidney is increased
by up to fourfold [9]. These various reports suggest that endothe-
lins may play a major role in the pathogenesis of tubulointerstitial
fibrosis characteristic of progressive renal disease [1, 10].
In patients with pre-existing impaired renal function, the prin-
cipal clinical risk factor determining the rapidity of subsequent
decline in renal function is now recognized as the magnitude of
proteinuria [11], while the main histological predictor of decline is
the extent of tubulointerstitial damage [1, 10]. Since the proximal
tubule is the site of reclamation of virtually all filtered proteins,
these observations suggest that filtered proteins might be a major
cause of proximal tubular cell injury. Few studies have considered,
however, that filtered proteins other than albumin might be
tubulo-toxic. In particular, the potential adverse effects of filtered
plasma lipoproteins on proximal tubular functions [12] have not
been investigated.
High density lipoprotein (HDL) particles (8 to 12 nm) are the
smallest subclass of lipoproteins [13]; they are found in normal
urine [14] but their physiological role is uncertain. One suggestion
is that filtered HDL may serve to deliver cholesterol and fatty
acids to proximal tubular cells, as these cells have a constant high
level of endocytic activity and membrane turnover [15]. Interest-
ingly, in nephrotic diseases, vastly increased amounts of HDL may
be filtered, and in these states HDL is the major urinary lipopro-
tein [16, 17]. In a previous study, we showed that native human
HDL was not directly toxic to cultured human renal proximal
tubular cells [18]. In the present study, we have sought to
investigate whether HDL particles might have indirect, potentially
pathogenic effects on proximal tubular cell function by investigat-
ing their influence on the release of the tubular-derived cytokine,
ET-1. We found purified human HDL to stimulate ET-1 produc-
tion by cultured human renal proximal tubular cells in a time- and
dose-dependent manner, apparently mediated by HDL apoli-
poproteins, through a mechanism independent of protein kinase
C activation.
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Methods
Cell culture
Human renal proximal tubular cells were cultured from healthy
nephrectomy tissue as previously described [5, 18]. The cells were
established in serum-free DMEM/F12 supplemented with triiodo-
thyronine (4 pg/mi), hydrocortisone (36 nglml), insulin (5 jig/mi),
transferrin (5 jig/mi), selenium (5 ng/ml) and epidermal growth
factor (10 ng/ml) [5, 18, 19]. All experiments were performed at
confluency or "near-confluency" (>90%) apart from the experi-
ments whose results are listed in Tables 1 and 2 (50 to 75%
confluent), using cells at up to passage 4 only. Experimental
incubation medium consisted of serum-free DMEMIF12 supple-
mented with transferrin (5 jig/mI), penicillin (100 U/mi), strepto-
mycin (100 jig/mi) and amphotericin (250 ng/ml); HDL and other
agents were added to this medium. Cell supernatants were
collected at various time points and were stored at —70°C until
assayed. The cell monolayers were washed and then were dis-
solved in 0.1 M NaOH for subsequent protein estimation by the
Bradford method.
Endothelin-1 immunoradiometric assay
Cellular ET-1 production was assayed using a specific two-site
immunoradiometric assay (IRMA) developed at the Middlesex
Hospital, London as described previously [5]. This assay was able
to detect 0.15 pg per tube which corresponds to 3 pg/ml of cell
supernatants. Each sample was assayed in duplicate and the
results are expressed as pg ET-1/mg cell protein to allow for
inter-well or inter-flask variation in cell number.
Preparation of lipoproteins
Blood samples from healthy human volunteers were collected
into an anticoagulant-preservative mixture containing EDTA,
protease inhibitors and antibiotics and the plasma collected by
centrifugation at 4°C [20]. Total HDL (d 1.063 to 1.21 g/ml),
HDL2 (d 1.063 to 1.125 gfml) and HDL3 (d 1.125 to 1.21 g/ml)
were obtained by differential ultracentrifugation flotation and
were washed once at their limiting density; HDL3 was further
purified by heparin-Sepharose chromatography to remove apoE-
containing particles [21, 22]. Modifications of HDL3 were carried
out as described previously [21—24]. In brief, fully delipidated
HDL (apoHDL) was obtained by methanol and diethyl ether
extraction and partially-delipidated HDL3 (PdHDL3), lacking the
hydrophobic neutral lipid core, by treatment with heptane. Ni-
trosylation of HDL3 was accomplished with tetranitromethane
and preparation of apoA-II-enriched HDL3 (A-II-HDL3) by
incubation of HDL3 with excess apoHDL, thereby permitting
apoA-II to displace apoA-I from the HDL3 surface. All HDL
fractions were dialyzed against 10 m sodium phosphate buffer,
pH 7.4 containing 145 ifiM NaCl and 0.3 mivi EDTA and were
sterilized by passage through a 0.2 jim filter. Lipoprotein concen-
trations are expressed in terms of their protein content as
measured by the method of Lowry et al [25] using bovine serum
albumin (BSA) as standard or of their total cholesterol content as
estimated using a commercial reagent (Boehringer Mannhein
UK, Lewes, East Sussex, UK).
Cyclic AMP estimation
Cellular cyclic AMP (cAMP) production was measured accord-
ing to the method described by Kempson et al [26]. In brief, cells
Table 1. Effect of whole plasma HDL on ET-1 release by subconfluent
cultured human renal proximal tubular cells
HDL
ET-1
pg/mg cell protein/48 hr
mM
cholesterol' igprotein/ml
0.000 0 1347 417
0.125 213 2681 269"
0.250 425 2869 108"
0.500 850 2708 687"
0.750 1275 2829 323"
1.000 1700 3718 135"
2.000 3400 4771 1106b
4.000 6800 5402 687"
° 1 mM HDL-cholesterol is equivalent to 1.7 mg HDL-protein/mlbP < 0.05 vs. control at all concentrations (N = 3)
were washed twice with phosphate buffered saline (PBS) and
incubated with 1 ml of serum-free control medium containing 0.5
mM 3-isobutyl-1-methyl-xanthine to inhibit the activity of phos-
phodiesterase. Forskolin (25 jiM) as a positive control or the test
HDL (500 pg'ml) were then added for one hour at 37°C.
Incubations were stopped by washing the cells four times with
ice-cold PBS and ice-cold 0.6 M perchioric acid was added (1
ml/well) to extract intracellular cAMP. After standing on ice for
10 minutes, the acid extracts were removed and neutralized by
addition of 0.5 ml of 2.8 nirI KHCO3. Any precipitates were
removed by centrifugation and then the cAMP in the supernatants
was measured by a commercial radioimmunoassay ([125IJcAMP
kit, Amersham Interational Plc, Amersham, UK) without preacety-
lation.
Materials
Serum-free DMEMIF12 was obtained from Gibco BRL (Ux-
bridge, UK), staurosporine from TCS Biologicais Ltd (Botolph
Claydon, Bucks, UK) and tissue culture 12-well plates and flasks
from Falcon (Becton Dickinson, Oxford, UK). All other reagents
were obtained from Sigma Chemical Co. (Poole, Dorset, UK).
Statistical analyses
All results are expressed as means SEM, Unpaired Student's
t-test was used for statistical comparisons and was considered
significant if the P value was less than 0.05.
Results
Effect of increasing HDL concentration on ET-1 production
Subconfluent cells were incubated for a total of five days with
media containing different concentrations of whole HDL; fresh
HDL-containing medium was added after 72 hours and the
supernatants collected after a further 48 hours for measurement
of ET-1. A twofold increase in ET-1 production over control wells
was noted up to 0.75 mi HDL-cholesterol, followed by further
increases in ET-1 production up to 4.00 mM HDL-cholesterol
(Table 1). Parallel incubations with LDL at 0.75 m cholesterol
showed a smaller (34 6%, N =3) though significant increase in
ET-1 production over controls (control: 1063 45 pg/mg cell
protein/48 hr; LDL: 1409 39 pg/mg cell protein/48 hr).
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Incubation time, hours
Fig. 1. Time course of HDL3-induced production of ET-1 by confluent
human renal tubular cells. Cultured cells were incubated with control
media (0) or with HDL1-containing media (A; 500 jg/m1) for up to 24 hr.
Each point is the mean value from a representative experiment of two,
carried out in triplicate wells; error bars representing SEM are as shown or
occur within the symbol. * Significantly (P < 0.05) greater than controls.
ET-1 p
pg/mg cell
Confluent
roduction
protein/24 hr
Subconfluent
Control medium 390 15 1419 60
HDL2b
HDL3b
ApoHDL3"
930 69*
984 58*
645 40*
2860 254*
2848 21o
2308 93
Time course of HDL3 stimulation of ET-1 production
In control cells, there was a near linear increase in ET-1
production (from 53 to 374 pg/mg cell protein) during a 12 hour
incubation period before reaching a plateau (Fig. 1). A similar
pattern was observed when HDL3 was added to the incubation
media except that ET-1 production was almost twofold higher at
each time point.
Comparison between HDL2, HDL3 and apoHDL3 in confluent
and subconfluent cells
The two major HDL subclasses, HDL2 and HDL3, elicited
similar stimulatory effects on ET-1 production in confluent cells
over a 24 hour period (Table 2). A free solution of apolipopro-
teins from HDL3 (apoHDL3), also enhanced the yield of ET-1,
though less effectively than whole HDL3. Subconfluent cells
(—75% confluency) grown in control media produced up to four
times more ET-1 than confluent cells within the same incubation
Concentration
jsg/ml
ET-production pg/mg cell protein/12 hr
HDL3 dHDLs
0 602±6
250 958 20* 1042 29*
500 1021 29* 1124 16
1000 978 ioa 953 23
Concentration
pg/ml
ET-1 production pg/mg cell protein/12 hr
HDL3 TNM-HDL3
0 215±9
10 281±12a 227±10
100 368±3a 283±6
1000 846 9* 752 20
period. However, the stimulatory effects of HDL2, HDL3 and
apoHDL3 were similarly increased so that the differences between
treated and untreated cells were maintained.
Comparison between HDL3 and partially-delipidated HDL3 or
TNM-modified HDL3
Because apolipoproteins may have impaired biological activi-
ties [27] and perhaps nonphysiological, membrane-perturbing
effects [23] when in free solution, we also studied the effect of
partial delipidation of HDL3 on ET-1 production. Such PdHDL3,
essentially a complex of HDL3 apolipoproteins and endogenous
phospholipid, had an equal ability to stimulate cellular production
of ET-1 when compared to native HDL3 (Table 3). Since it
appeared that the apolipoprotein constituents of HDL were
largely responsible for the increase in production of ET-1, the
effect of TNM modification of HDL3 was examined next. This
reagent chemically modifies the apolipoproteins in HDL surfaces
either by nitrosylation of tyrosine residues and/or by cross-linking
individual molecules. This prevents their recognition by certain
HDL receptors, including those implicated in cellular cholesterol
homeostasis [28] and platelet activation [21] but not those in-
volved in intracellular Ca2 signalling [29]. However, TNM
modification of HDL3 did not abolish the increase in ET-1
production, although a significantly smaller (P < 0.05) response
than native HDL3 was observed at the three concentrations (10,
100 and 1000 g/ml) tested (Table 4).
Preincubation with BSA; comparison between HDL3 and ApoA-
Il-enriched HDL3
Since the stimulatory effect of HDL could be attributed pre-
dominantly to its apolipoprotein components, incubations with
delipidated BSA were performed to exclude the possibility that
the observed effects of HDL were due solely to protein repletion.
Cells incubated for 24 hours with BSA (500 jLg/ml) showed a 60%
increase in ET-1 production compared to control wells, but this
7
* Table 3. Comparison of the effects of HLD3 and PdHDL3 on ET-1
production by confluent human renal tubular cells
2
I
800
600
400
200
0
a Au values were significantly (P < 0.05) greater than control cells (N =
3)
Table 4. Effect of tetranitromethane (TNM) modification of HDL3 on
its ability to stimulate ET-1 production by confluent renal tubular cells
0 4 8 12 16 20 24
a Significantly (P < 0.05) greater than the corresponding TNM-HDL3
treated cells at all concentrations tested
Table 2. Production of ET-1 in confluent and subconfluent renal
tubular cells in response to HDL2, HDL3 and apoHDL3
ap < 0.05 vs. control medium (N = 3)
bAll test fractions were added at 500 eg/ml for 24 hr
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24 hr FT-i production pg1mg cell protein/24 hr
No preincubationa Preincubationa
Control
BSA
HDL3
A-II-HDL3
886 58
1406 87
1748 59b
1492 29
926 17
1248 27
1594 65b
1442 32
was significantly less (P < 0.05) than that of HDL3 (Table 5). A
similar stimulatory effect of BSA on FT-i production in endothe-
hal cells has been reported previously [301. Interestingly, although
A-II-HDL3 also enhanced ET-1 production compared to controls,
its effect was less potent (P < 0.05) than that of HDL. This
suggests that apoA-I might be the major apolipoprotein in HDL
mediating the cellular response. When the cells were preincu-
bated for 24 hours with BSA (250 j.ig/ml) the yields of ET-1
decreased, but nevertheless the relative subsequent responses to
BSA, HDL3 and A-II-HDL3 were maintained.
Time taken to activate ET-1 pmduction
To determine the minimum time that cells needed to be
exposed to HDL for "activation" of FT-i production to occur,
lipoprotein-free medium was collected for 12 hours after different
treatment periods with HDL3 (500 gIml). A one hour exposure
to HDL3 appeared sufficient to activate the cells, but maximum
enhancement of ET-1 production required about six hours incu-
bation (Fig. 2).
Effect of PMA and HDL3
To ascertain whether PKC might have a role in mediating the
effect of HDL3, the stimulatory effect of PMA (1 M) on ET-1
production was compared to that of HDL3 (500 gIml) both singly
and in combination. The results (expressed as a % of control)
showed that the two agents had an additive effect: PMA (280
13%), HDL3 (256 7%), and PMA plus HDL3 (515 21%).
This additive effect of PMA and HDL3 on ET-1 production was
investigated further. Cells were incubated with control, HDL3 or
PMA containing medium for 24 hours; each group was then
assigned to a further 24 hour incubation with control, HDL3 or
PMA media. In agreement with the above findings, PMA and
HDL3 stimulated ET-1 production by approximately twofold in
the first 24 hours compared to control cells (Fig. 3). As expected,
PMA did not stimulate ET-1 production in cells previously
exposed to PMA for 24 hours, presumably because of PKC
depletion [311. However, PMA was able to stimulate ET-1 pro-
duction two- to threefold both in control cells and in cells
pre-exposed to HDL3. By contrast, HDL3 stimulated ET-1 pro-
duction in all three groups, that is, in cells pre-exposed to control
media, to HDL3 or to PMA. Clearly, the stimulatory effect of
HDL3 on FT-i production differs from that of PMA: it is
independent of PKC activation, it is not depleted by pre-incuba-
tion, and it is long-lasting persisting for a further 24 hours.
I I I I
0 2 4 6 8 10 12
Length of previous incubation, hours
Fig. 2. Time taken for HDL3 to activate production of ET-1 by confluent
human renal tubular cells. Cultured cells were preincubated for different
time periods (up to 12 hr) with control media (0) or with HDL3-
containing media (A; 500 igIml) and then incubated with control media
alone for a further 12 hr to measure ET-1 production. Each point is the
mean value of triplicate wells; error bars representing SEM are as shown or
are within the symbol. * P < 0.05 vs. controls; + P < 0.05 vs. different
HDL.3 concentrations.
Effect of staurosporine on HDL3 stimulated ET-1 production
Coincubation with the PKC inhibitor staurosporine (1 flM) had
no effect on HDL3-stimulated (500 g/ml) ET-1 production (839
55 pg/mg cell protein/12 hr compared to 906 65 without
staurosporine, P < 0.05). Incubation with higher concentrations
of staurosporine (10 nM) also failed to decrease ET-i production
by HDL3-stimulated cells (817 44) but higher doses (100 nM)
were toxic to the cells (data not shown).
Effect of HDL3 on cellular cyclic AMP production
Cells were incubated with 3-isobutyl-1-methyl-xanthine (0.5
mM) to inhibit phosphodiesterase activity, and then treated with
either the test HDL3 (in its fully delipidated form, 500 g/ml) or
forskolin (25 M), a known stimulator of the /3-catalytic subunit of
adenylate cyclase. Although forskolin clearly stimulated cAMP
production (123 18 pg/mg cell protein/h vs. 37.1 4.9 in
controls, N = 4, P < 0.05) no enhancement was seen with
delipidated HDL3 (23.8 2.0 pg/mg cell protein/hr).
Discussion
Conventionally, the central function of HDL is recognized as
the transport of cholesterol from peripheral tissues to the liver for
excretion, a process termed reverse cholesterol transport. There is
now increasing appreciation that HDL may have other functions
[32]. In particular, HDL is able to trigger a variety of intracellular
signalling pathways in many cell types; these effects are unrelated
to cholesterol homeostasis and are not reproduced by LDL [32].
The best known is the action of HDL as a potent mitogen for both
Table 5. Effect of preincubation with delipidated BSA on HDL3- and
A-II-HDL3-stimulated production of ET-1 by confluent human renal
tubular cells
* Cells were preincubated with delipidated BSA (250 Wml) for 24 hr
before addition of test fractions (500 g/ml) for an additional 24 hr
b Significantly (P < 0.05) greater than the corresponding A-II-HDL3
and BSA values
+ *
*
0
'N
0.
C0
0
0
0.
Lu
500
400
300
200
100
0
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not normally stored in cells and its production is transcriptionally
_____________
regulated [41].
The signalling pathway required for HDL-induced stimulation
of ET-1 differs from the mitogenic and other actions of HDL since
PKC is not involved. Whether other protein kinases can be
activated by HDL is uncertain, although we have found in
preliminary experiments (unpublished observations) that HDL
induces a different pattern of protein phosphorylation in our
tubular cells compared to PMA. Alternatively, other signalling
pathways may be involved. Although apoA-I-mediated cholesterol
effiux from cultured adipocytes does not require cAMP produc-
tion [38], a cAMP-dependent pathway has been implicated in the
release of human placental lactogen induced by HDL or apoA-I
[42, 43]. But our findings did not support a role for this mecha-
nism in HDL-stimulation of ET-1 release; cAMP levels in renal
tubular cells were unaffected by incubation with HDL apolipopro-
teins. Incubation of HDL3 with cultured human skin fibroblasts
[29] or vascular smooth muscle cells [44] is reported to invoke
rapid and transient rises in intracellular calcium, [Ca2]1. These
effects of HDL3 are considered to be independent of the lipid-
transporting functions of the particles [29, 32] and, at least in skin
fibroblasts, can be mediated by TNM-HDL3. Nevertheless, it
seems implausible that such a mechanism operates in our tubular
cells; prior exposure to PMA does not block HDL-stimulated
ET-1 production, whereas rises in [Ca2]1 are inhibited by such
treatment [29, 44]. Clearly, additional studies will be needed to
elucidate both the initial trigger and the second messenger
system(s) involved in HDL-induced release of ET-1.
In conclusion, our results add to the increasing recognition of
HDL as an agent with potentially diverse actions in the kidney.
Although the amounts of ET-1 secreted by human proximal
tubular cells (400 pg/mg cell protein/12 hr) are considerably less
than those secreted by porcine aortic endothelial cells (15000
pg/106 cells/48 hr) [45], they compare favorably with those se-
creted by human mesangial cells (60 pg/b6 cells/6 hr) [46] and
human inner medullasy collecting duct cells (120 pg/mg cell
protein/24 hr) [47]. ET-1 is a potent mitogen for a variety of
different cell types [3, 8, 48] and we have found that significant
tubular cell replication occurs at concentrations as low as 10'5M
(unpublished data). This points to a possible physiological role for
tubular-derived ET-1 as an autocrine factor involved in tubular
cell regeneration; filtered HDL could facilitate this process by
maintaining basal levels of ET-1. A pathophysiological role is also
indicated by our studies inasmuch as the influence of HDL on
tubular ET-1 production appears to be dose-dependent (up to at
least 7 mg/ml at which dose no toxic effects are apparent; Table 1).
Concentrations of HDL in the glomerular filtrate of nephrotic
kidneys may approach this level [18], and it is thus possible that
the high quantities of filtered HDL in nephrosis may markedly
up-regulate ET-1 production by proximal tubular cells. Since
tubular ET-1 is released largely basolaterally [6, 8], enhanced
tubular ET-1 production could lead to important effects on the
renal microcirculation [7], interstitial fibroblasts [8] and intersti-
tial macrophages [4], if sustained by HDL. This could in turn lead
to tubular ischaemia, interstitial fibroblast proliferation, matrix
deposition and infiltration of activated macrophages, features
characteristic of the tubulointerstitial changes seen in progressive
renal diseases associated with chronic proteinuria.
..
w
2000
3::/
500
Control
preincubation
HDL3
pretncubation
PMA
preincubation
0
.
.
c'i 0
24 4824 48 24 48
Incubation time, hours
Fig. 3. Effect of sequential 24 hour incubations with control media and
HDL3- or PMA-containing media on production of ET-1 by confluent
human renal tubular cells. Groups of cultured cells were preincubated with
control media (0), HDL3 (A; 500 g/ml) or PMA (U; 1 jM) for 24 hours
and then each group assigned to an additional 24 hour incubation with
control, HDL3 or PMA media. All points are mean values (N = 3) of ET-1
production. For clarity, error bars representing the SEM have not been
plotted but were always less than 10% of each mean.
normal and transformed cells [33, 34]. Such cellular proliferation
induced by HDL seems to involve a PKC-dependent pathway and,
at least in bovine aortic endothelial cells, is associated with the
phosphorylation of a 27 kD protein, as yet unidentified [35]. The
major apolipoprotein of HDL, apoA-I, is considered the principal
mitogenic constituent in the HDL particles, but other minor
apolipoproteins such as apoC-Ill may also be mitogens for some
cells [34]. Other effects of HDL which are deemed to be apoli-
poprotein and PKC mediated are the synthesis and release of
placental lactogen [36, 37] and the translocation of intracellular
cholesterol to the cell surface prior to its removal [31, 38].
Effects of HDL on kidney cells have not been extensively
studied. In established animal renal epithelial and tubular cell
lines, it is apparent that HDL can act both as a potent mitogen
[39] and as a morphogen [40], while we have reported that both
HDL2 and HDL3 are mitogenic for cultures of human renal
tubular cells [18]. Hence, it is possible that filtered HDL may play
a physiological role in the regeneration and differentiation of
renal tubular cells by, as yet, undetermined signalling pathways.
Indeed, our present findings suggest that exposure of human
tubular cells to HDL will trigger a novel intracellular signalling
pathway, independent of PKC activity, that stimulates ET-1
production. Such intracellular activation is not the result of
cellular repletion of protein or cholesterol; rather it appears to be
mediated by HDL apolipoproteins, primarily apoA-I. Binding by
the conventional HDL receptors implicated in cholesterol ho-
meostasis was excluded as the first step, although brief exposure,
less than one hour, of the cells to the HDL was sufficient to
achieve prolonged production of ET-1. Although not directly
measured, it is likely that changes in cellular synthesis of ET-1
directly determined the ET-1 levels in our culture media; ET-1 is
1320 Ong et al: HDL stimulates tubular ET-1 production
Acknowledgments
This work was made possible by a grant from the National Kidney
Research Fund to A.C.M. Ong. We thank Butch Persaud for technical
assistance, and Dr. Z. Varghese and Dr. C. Teahan for helpful discussion.
Reprint requests to Dr. A. CM. Ong Department of Medicine, University
College London Medical School, The Rayne Institute, University Street,
London WC1E 6.1.1, Englan4 United Kingdom.
References
1. Oo ACM, FINE LG: Loss of glomerular function and tubulointersti-
tial fibrosis: Cause or effect? Kidney mt 45:345—351, 1994
2. YANAGISAWA M, KuRIun H, KIMURA S, TOMOBE Y, KOBAYASHJ M,
MITSUI Y, YAZAKI Y, GoTo K, MASAKI T: A novel potent vasocon-
strictor peptide produced by vascular endothelial cells. Nature 332:
411—415, 1988
3. TAKuwAN, TAKUWA Y, YANAGISAWA M, YAMASHITA K, MASAKI T: A
novel vasoactive peptide endothelin stimulates mitogenesis through
inositol lipid turnover in Swiss 3T3 fibroblasts. .1 Biol Chem 264:7856—
7861, 1989
4. ACHMAD T, RAo G: Chemotaxis of human blood monocytes towards
endothelin-1 and the influence of calcium channel blockers. Biochem
Biophys Res Commun 189:994—1000, 1992
5. ONG ACM, JOWETr TP, SCOBLE JE, O'SHEA JA, VARGHESE Z,
MooRIiaD JF: The effect of cyclosporin A on endothelin synthesis by
cultured human renal cortical epithelial cells. Nephrol Dial Transplant
8:748—753, 1993
6. K0IJAN DE, PADIUA F: Endothelin-1 is an autocrine factor in rat
inner medullary collecting ducts. Am .1 Physiol 263:F607—F612, 1992
7. KON V, YosmolcA T, FoGo A, ICHIKAwA I: Glomerular actions of
endothelin in vivo. .1 Clin Invest 83:1762—1767, 1989
8. ONG ACM, JOWETF TP, FIRTH JD, BURTON S, KITAMURA M, FINE
LG: A new paracrine loop implicated in human tubulo-interstitial
disease: Tubular-derived endothelins modulate renal interstitial fibro-
blast function. (abstract) JAm Soc Nephrol 4:473, 1993
9. Osusio S, BENIGNI A, BRUZZI I, CORNA D, PERICO N, ZOJA C,
BENAITI L, REMUZZI G: Renal endothelin gene expression is in-
creased in remnant kidney and correlates with disease progression.
Kidney mt 43:354—358, 1993
10. BOHLE A, CHRIST H, GRUND KE, MACKENSEN A: The role of the
interstitium of the renal cortex in renal disease. Contrib Nephrol
16:109—114, 1979
11. PETERSON IC, BURKART J, GREENE T, HEBERT L, KING A, KLAHR S,
MAsSNY S, SEIFTER J: The effect of blood pressure control on
progression of renal disease depends on level of proteinuria at
baseline evaluation. (abstract) JAm Soc Nephrol 4:254, 1993
12. MOORHEAD IF, Ci-i MK, EL-NAHAS M, VARGHESE Z: Lipid neph-
rotoxicity in chronic progressive glomerular and tubulointerstitial
disease. Lancet 2:1309—1311, 1982
13. EISENBERG S: High density lipoprotein metabolism. J Lipid Res
25:1017—1058, 1984
14. SEGAL P, GIDEZ LI, VEOA GL, EDELSTEIN D, EDER HA, ROHEIM PS:
Apoproteins of high density lipoproteins in the urine of normal
subjects. J Lipid Res 20:784—788, 1979
15. PETERSON DR, HJELLE JT, CARONE FA, MOORE PA: Renal handling
of plasma high density lipoprotein. Kidney mt 26:411—421, 1984
16. GoMo ZAR, HENDERSON LO: High density lipoprotein apoproteins in
urine: II. Enzyme-linked immunoassay of apolioprotein A-i. Clin
Chem 34:1781—1786, 1988
17. SHORE VG, FoRm T, Llcrr H, LEwis SB: Serum and urinary
lipoproteins in the human nephrotic syndrome: Evidence for the renal
catabolism of lipoproteins. Metabolism 31:258—268, 1982
18. ONG ACM, Mooiu-iE,4.o IF: Tubular lipidosis: Epiphenomenon or
pathogenetic lesion in human renal disease? Kidney mt 45:753—762,
1994
19. DETRISAC CJ, SENS MA, GARRIN AJ, SPICER SS, SENS DA: Tissue
culture of human kidney epithelial cells of proximal tubule origin.
Kidney mt 25:383—390, 1984
20. OSBORNE IC: Delipidation of plasma lipoproteins. Meth Ensymol
128:213—222, 1986
21. DESAI K, BRUCKDORFER KR, HUTrON RA, Owui JS: Binding of
apoE-rich high-density lipoprotein particles by saturable sites on
human blood platelets inhibits agonist-induced platelet aggregation. J
Lipid Res 30:831—840, 1989
22. GILLETr MPT, OWEN IS: Characteristics of the binding of human and
bovine high-density lipoproteins by blood stream forms of the African
trypanosome, Trypanosoma bmcei brucet. Biochim Biophys Acta 1123:
239—248, 1992
23. GIuErr MPT, OWEN IS: Comparison of the cytolytic effects in vitro
on T,ypanosoma brucei brucei of plasma, high density lipoproteins, and
apolipoprotem A-I from hosts both susceptible (cattle and sheep) and
resistant (man and baboon) to infection. .1 Lipid Res 33:513—523, 1992
24. OWEN JS, GILLETT MPT, HUGHES TE: Transgenic mice expressing
human apolipoprotein A-i have sera with modest trypanolytic activity
in vitro but remain susceptible to infection by Ttypanosoma brucei
brucei. J Lipid Res 33:1639—1646, 1992
25. MARICWELL MAK, His SM, BIEBER LL, TOLBERT NE: A modifica-
tion of the Lowry procedure to simplifi protein determination in
membrane and lipoprotein samples. Anal Biochem 87:206—210, 1978
26. KEMPSON SA, MCATEER JA, AL-MAHROUQ HA, DOUSA TP, DOUGH-
ERTY GS, EvAN AP: Proximal tubule characteristics of cultured
human renal cortex epithelium. J Lab Clin Med 113:285—296, 1989
27. INNERARITY TL, PTTAS RE, MANIJ RW: Binding of arginine-rich (F)
apoprotein after recombination with phospholipid vesicles to the low
density lipoprotein receptors of fibroblasts. .1 Biol Chem 254:4186—
4190, 1979
28. BRINTON EA, Og,&M JF, CHEN C-H, ALBERS JJ, BIERMAN EL: Binding
of high density lipoprotein to cultured fibroblasts after chemical
alteration of apoprotein amino acid residues. J Biol Chem 262:7439—
7442, 1986
29. PORN MI, AKERMAN KEO, SLOTFE JP: High-density lipoproteins
induce a rapid and transient release of Ca2 in cultured fibroblasts.
Biochem J 279:29—33, 1991
30. HEXUM TD, HOEGER C, RIVIER JE, BAIRD A, BROWN MR: Charac-
terisation of endothelin secretion by vascular endothelial cells. Bio-
chem Biophys Res Commun 167:294—300, 1990
31. MENDEZ Al, ORAM JF, BIERMAN EL: Protein kinase C as a mediator
of high density lipoprotein receptor-dependent efflux of intracellular
cholesterol. .1 Biol Chem 266:10104—10111, 1991
32. AILNAUD G: Cellular signal transductants: a new role for HDL. Cuir
Opin Lipidol 3:222—226, 1992
33. TAUBER JP, CHENG J, GosPoDARowlcz D: Effect of high and low
density lipoproteins on proliferation of cultured bovine vascular
endothelial cells. J Clin Invest 66:696—708, 1980
34. CHEN JK, LABRAKE-FARMER S, MCCLURE DB: Purified HDL-apoli-
poproteins, Al and CIII, substitute for HDL in promoting the growth
of SV-40-transformed REF52 cells in serum-free medium. J Cell
Physiol 128:413—420, 1986
35. DARBON IM, TOURNIER IF, TAUBER IF, BAYARD F: Possible role of
protein phosphorylation in the mitogenic effect of high density
lipoproteins on cultured vascular endothelial cells. J Biol Chem
261:8002—8008, 1986
36. HARMAN I, ZEITLER P. GANONG B, BELL RM, HANDWERGER 5:
Sn-1,2-Diacylglycerols and phorbol esters stimulate the synthesis and
release of human placental lactogen from placental cells: A role for
protein kinase C. Endocrinology 119:1239—1244, 1986
37. HANDWERGER 5, QUAItFORDT S, BARRE1T J, HARMAN I: Apolipopro-
teins A!, All and CI stimulate placental lactogen release from human
placental tissue. J Clin Invest 79:625—628, 1987
38. TI-IERET N, DELBART C, AGUIE G, FRUCHART IC, VASSAUX G,
AILHAUD U: Cholesterol efflux from adipose cells is coupled to
diacylglycerol production and protein kinase C activation. Biochem
Biophys Res Commun 172:1361—1368, 1990
39. Gosvoaucowicz D, COHEN DC, MASSOGLIA 5: Stimulation of the
proliferation of the Madin-Darby Canine Kidney (MDCK) epithelial
cell line by high-density lipoproteins and their induction of 3-hydroxy-
3-methylglutaryl coenzyme A reductase activity. J Cell Physiol 117:76—
90, 1983
40. GOSPODAROWICZ D, LEvINE I, MASSOGUA S. WOOD I: Comparison of
the ability of basement membranes produced by corneal endothelial
and mouse-derived endodermal PF-HR-9 cells to support the prolif-
eration and differentiation of bovine kidney tubule epithelial cells in
vitro. J Cell Biol 99:947—961, 1984
Ong et al: HDL stimulates tubular ET-1 production 1321
41. MASAKI T, KIMuRA S, YANAGISAWA M, GoTo K: Molecular and
cellular mechanism of endothelin regulation: Implications for vascular
function. Circulation 84:1457—1468, 1991
42. Wu YQ, JORGENSEN EV, HANDWERGER S: High density lipoproteins
stimulate placental lactogen release and adenine 3'5'-monophosphate
(cAMP) production in human trophoblast cells: Evidence for cAMP
as a second messenger in human placental lactogen release. Endocri-
nology 123:1879—1884, 1988
43. Wu YQ, HANDWERGER S: High density lipoproteins stimulate molec-
ular weight 80K protein phosphorylation in human trophoblast cells:
Evidence for a protein kinase-C-dependent pathway in human pla-
cental lactogen release. Endocrinology 131:2935—2940, 1992
44. Bocmov V, TKACHUK V, BUHLER F, RESINK T: Phosphoinositide and
calcium signalling responses in smooth muscle cells: Comparison
between lipoproteins, Ang II, and PDGF. Biochem Biophys Res Comm
188:1295—1304, 1992
45. Kosics. T, SuzuKI N, MATSUMOTO H, ITO!-J Y, YASUFIARA T, ONDA
H, FuJIN0 M: Synthesis of the vasoconstrictor peptide endothelin in
kidney cells. FEBS Lett 249:42—46, 1989
46. ZOJA C, ORislo S, PERIc0 N, BENIGN! A, M0RIG! M, BENATrI L,
RAMBALDI A, REMUZZI G: Constitutive expression of endothelin gene
in cultured human mesangial cells and its modulation by transforming
growth factor-j3, thrombin and a thromboxane A2 analogue. Lab
Invest 64:16—20, 1991
47. Koiw DE: Endothelin production by human inner medullaiy col-
lecting duct cells. JAm Soc Nephrol 3:1719—1721, 1993
48. KOMuRO I, KURII-LARA H, SUG!YAMA T, TftJcs.Ku F, YAZAKI Y:
Endothelin stimulates c-fos and c-myc expression and proliferation of
vascular smooth muscle cells. FEBS Lett 238:249—252, 1988
